JPRN-UMIN000011089已完成2 期
Tri-modality strategy with Docetaxel plus five-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced esophageal cancer - Tri-modality strategy with DCF induction chemotherapy for locally advanced esophageal cancer (COSMOS)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Simultaneous or metachronous (within 5 years) double cancers, except for intramucosal tumor curatively resected by local therapy 2) Active infection requiring systemic therapy 3) Positive HBs antigen, HCV antibody or HIV antibody 4) Pregnant or lactating women or women of childbearing potential 5) Psychiatric disease 6) Patients requiring systemic steroids medication 7) Hypersensitivity for docetaxel, cisplatin or polysorbate 80 containing drug 8) Uncontrolled diabetes mellitus 9) Severe emphysema or pulmonary fibrosis 10) Unstable angina within 3 weeks, or with a history of myocardial infarction within 3 months. 11) Any other cases who are regarded as inadequate for study enrollment by the investigator.
研究者
相似试验
已完成
2 期
Phase II study of Docetaxel and CDDP and 5-FU for metastatic esophageal cancerEsophageal cancer with distant metastasis (Stage IVb or stage IVa with N4)JPRN-UMIN000002180OGSG45
已完成
2 期
Phase II study of Docetaxel and CDDP and 5-FU for metastatic esophageal cancerPatients to be registered Esophageal cancer with distant metastasis (Stage IVb or stage IVa with N4)JPRN-UMIN000000821OGSG45
已完成
不适用
Phase 1/2 Study of Docetaxel, CDDP and 5-FU therapy in Patients With Unresectable or Recurrent Esophageal Cancernresectable or recurrent esophageal cancerJPRN-UMIN000003633Department of Surgery, Graduate School of Medicine, Osaka University49
进行中（未招募）
不适用
Multicenter phase II study with docetaxel, 5-FU, leucovorin, and oxaliplatin in patients with metastatic or locally advanced gastric cancer or cancer of the esophagogastric junction- FLOTMetastatic or locally advanced gastric cancerEUCTR2005-004135-22-DEKrankenhaus Nordwest42
进行中（未招募）
不适用
DOCETAXEL COMBINED WITH PULSATILE ERLOTINIB (TARCEVA) IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) - DOPERLOMetastatic (stage IV) non-small cell lung cancer (NSCLC) who have not previously been treated with anticancer drugsEUCTR2007-001555-19-GRHellenic Cooperative Oncology Group